In Segment C, participants will receive ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Contributors will obtain treatment till ailment progression or perhaps the individuals are not able to tolerate the study drugs. Ubiquitin-linked proteins that regulate The steadiness of critical super enhancer-mediated proteins have https://howdoesabbv-744workincanc36790.weblogco.com/32027597/about-abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers